Results 91 to 100 of about 54,096 (328)
Catheterization and Cardiovascular Interventions, EarlyView.ABSTRACT Background Myeloproliferative neoplasms (MPN) are associated with an increased cardiovascular risk including acute coronary syndrome. However, there is a lack of comprehensive data regarding the rate of percutaneous coronary intervention (PCI), as well as the in‐hospital characteristics and outcomes for MPN patients.
Song Peng Ang +8 more
wiley +1 more source
Haematologica, 2014 Myelofibrosis is a myeloproliferative neoplasm that occurs de novo (primary myelofibrosis) or results from the progression of polycythemia vera or essential thrombocytemia (hereafter designated as secondary myelofibrosis or post-polycythemia vera ...
Mandy Brecqueville +12 more
doaj +1 more source
Updated recommendations on the use of ruxolitinib for the treatment of myelofibrosis
Hematology, 2022 Objectives Myelofibrosis is a rare bone marrow disorder associated with a high symptom burden, poor prognosis, and shortened survival. While allogeneic hematopoietic stem cell transplantation (HSCT) is the only curative treatment for myelofibrosis, the ...
Timothy Devos +4 more
doaj +1 more source
Survival following allogeneic transplant in patients with myelofibrosis.
Blood Advances, 2020 Allogeneic hematopoietic cell transplantation (HCT) is the only curative therapy for myelofibrosis (MF). In this large multicenter retrospective study, overall survival (OS) in MF patients treated with allogeneic HCT (551 patients) and without HCT (non ...
K. Gowin +67 more
semanticscholar +1 more source
Ruxolitinib in the treatment of polycythemia vera: patient selection and special considerations. [PDF]
, 2016 The discovery of JAK2 V617F mutation in the mid-2000s started to fill the gap between clinical presentation of polycythemia vera (PV), first described by Vaquez at the end of the 19th century, and spontaneous erythroid colony formation, reported by ...
Alberio, L., Blum, S., Martins, F.
core +2 more sources
Myelofibrosis biology and contemporary management
British Journal of Haematology, 2020 Myelofibrosis is an enigmatic myeloproliferative neoplasm, despite noteworthy strides in understanding its genetic underpinnings. Driver mutations involving JAK2, CALR or MPL in 90% of patients mediate constitutive JAK‐STAT signaling which, in concert ...
N. Gangat, A. Tefferi
semanticscholar +1 more source
Therapeutic targeting of chromatin alterations in leukemia and solid tumors
International Journal of Cancer, EarlyView.Abstract Alterations in chromatin conformation and post‐translational modification of histones have become increasingly recognized as critical drivers of cancer development, progression, and therapy resistance. Recent advances in drug development have led to the establishment of several highly selective small molecule inhibitors, several of which are ...
Florian Perner +7 more
wiley +1 more source
The degree of anisocytosis predicts survival in patients with primary myelofibrosis [PDF]
, 2016 Introduction: Red cell distribution width (RDW) provides a quantitative measure of anisocytosis and it is associated with the presence of subclinical systemic inflammation and a poor outcome in a variety of diseases when elevated.
Hariš, Višnja +10 more
core +1 more source
International Journal of Cancer, EarlyView.What's New? Current treatment goals for polycythemia vera, a myeloproliferative neoplasm characterized by JAK2 mutations, are mainly to prevent thrombosis. While ropeginterferon alfa‐2b treatment also reduces JAK2 mutation burden, the correlation between the hematologic and molecular responses remains to be clarified.
Seug Yun Yoon +15 more
wiley +1 more source
Blood Advances, 2020 PAC203 is a randomized dose-finding study of pacritinib, an oral JAK2/IRAK1 inhibitor, in patients with advanced myelofibrosis who are intolerant of or resistant to ruxolitinib.
A. Gerds +25 more
semanticscholar +1 more source